The goals of the Genetic Epidemiology and Risk Assessment (GERA) Program are to: 1) Utilize the tremendous advances in genetics and molecular biology in order to understand genetic, environmental, and gene-environment interactions in the etiology of cancer in human populations;2) Utilize these same advances in order to understand the molecular epidemiology of cancer prognosis and survivorship;and 3) Develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. Our cancer etiology studies use family-based, case-control and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as non-genetic risk factors and descriptive epidemiology. We are also addressing etiologic heterogeneity based on tumor phenotype. Our cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis;tumor biomarkers;and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics and bioinformatics. To achieve these goals we have assembled a team of 32 multidisciplinary investigators from over 10 divisions or departments. Total peer-reviewed funding is $8.81 M from 32.6 assigned grants, with 71% coming from the National Cancer Institute. Since 2008, the program has generated 622 publications, 43% reflecting intra-programmatic collaborations and 61% reflecting inter-programmatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, lymphoma, and mammographic breast density, as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan and Parker. The program makes extensive use of shared facilities. In the next 5 years, we will continue our innovative research in cancer etiology and prognosis with a focus on genomics, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682941
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$402,631
Indirect Cost
$149,608
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications